Multiplexed evaluation of a cell-based assay for the detection of antidrug neutralizing antibodies to panitumumab in human serum using automated fluorescent microscopy

Journal of Biomolecular Screening

Volumn 15, Issue 6, 2010, Pages 644-652

  Pennucci, Jason ^a   Swanson, Steve ^a   Kaliyaperumal, Arunan ^a   Gupta, Shalini ^a  

^a AMGEN INC   (United States)

Author keywords

epidermal growth factor; high content analysis; multiplexed cell based assay; neutralizing antibody detection

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; NEUTRALIZING ANTIBODY; PANITUMUMAB; RECOMBINANT VASCULOTROPIN; STAT1 PROTEIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CARCINOMA CELL; CELL ASSAY; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DRUG ANTIGENICITY; DRUG DETERMINATION; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; SERUM; AUTOMATION; BIOASSAY; BLOOD; DRUG EFFECTS; DRUG SCREENING; EVALUATION STUDY; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; PROCEDURES; PROTEIN TRANSPORT; SERODIAGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; AUTOMATION; BIOLOGICAL ASSAY; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; EPIDERMAL GROWTH FACTOR; HUMANS; MICROSCOPY, FLUORESCENCE; NEUTRALIZATION TESTS; PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

ORYCTOLAGUS CUNICULUS;

EID: 77955794430     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110370893     Document Type: Article

References (17)

1. Antonelli G., Dianzani F.: Development of antibodies to interferon beta in patients; technical and biological aspects. Eur Cytokine Network 1999 ; 10: 413-422.
2. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J-J., Martin-Dupont P., et al. Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002 ; 346: 469-475. (Pubitemid 34441737)
3. Swanson SJ: New technologies for the detection of antibodies to therapeutic proteins. Dev Biol 2003 ; 112: 127-133.
4. Wadhwa M., Bird C., Dilger P., Gaines-Das R., Thorpe R.: Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods 2003 ; 278: 1-17.
5. Gupta S., Indelicato SR, Jethwa V., Kawabata T., Kelley M., Mire-Sluis AR, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007 ; 321: 1-18.
6. Wala I., Swanson SJ, Jing S.: A non-radioactive method for detecting neutralizing antibodies against therapeutic proteins in serum. J Pharm Biomed Anal 2007 ; 45: 583-589.
7. Mire-Sluis AR: Challenges with current technology for the detection, measurement and characterization of antibodies against biological therapeutics. Dev Biol (Basel) 2002 ; 109: 59-69.
8. Carpenter G., Cohen S.: Epidermal growth factor (minireview). J Biol Chem 1990 ; 265: 7709-7712.
9. Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med J 1991 ; 47: 87.
10. Sridhar S., Seymour L., Shepherd F.: Inhibitors of epidermal-growth- factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet 2003 ; 4: 397-406.
11. Bleeker W., Lammerts van Bueren J., van Ojik H., Gerritsen A., Pluyter M., Houtkamp M., et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004 ; 173: 4699-4707.
12. Schlessinger J.: Signal transduction by allosteric receptor oligomerization. Trends Biochem Sci 1998 ; 13: 443-447.
13. David M., Wond L., Flavell R., Thompson S., Wells A., Larner A., et al. STAT activation by epidermal growth factor (EGF) and amphiregulin. J Biol Chem 1996 ; 271: 9185-9188.
14. Darnell JE: STATs and gene regulation. Science 1997 ; 277: 1630-1635.
15. Wei X., Swanson SJ, Gupta S.: Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. J Immunol Methods 2004 ; 293: 115-126.
16. Haussler U., von Wichert G., Schmid R., Keller F., Schneider G.: Epidermal growth factor activates nuclear factor-°B in human proximal tubule cells. Am J Physiol Renal Physiol 2005 ; 289: F808 - F815.
17. Mire-Sluis AR, Barrett YC, Devanaranyan V., Koren E., Liu H., Maia M., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004 ; 289: 1-16.